Zacks Investment Management’s Theravance Biopharma TBPH Stock Holding History

Zacks Investment Management’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-21,603	Closed	-$861K	–	658
2017 Q2	$861K	Buy	21,603 +959	+5%	+$36.9K	0.02%	401
2017 Q1	$760K	Buy	20,644 +8,396	+69%	+$268K	0.02%	411
2016 Q4	$390K	Buy	12,248 +5,583	+84%	+$173K	0.01%	471
2016 Q3	$242K	Buy	+6,665	New	+$186K	0.01%	531

Other funds holding TBPH

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Zacks Investment Management's TBPH Position: Q3 2017 in Review

Zacks Investment Management sold out of Theravance Biopharma (TBPH) in Q3 2017, closing a stake of 21,603 shares — an estimated $861K sold.

Zacks Investment Management first reported a position in TBPH in Q3 2016 and held it in 4 quarters. The position peaked at $861K in Q2 2017. 84 funds tracked by Wall St. Rank hold TBPH as of Q3 2017.

Zacks Investment Management reported no remaining Theravance Biopharma position as of Q3 2017 after selling out during the quarter.
Zacks Investment Management sold 21,603 Theravance Biopharma shares in Q3 2017, an estimated $861K.
Zacks Investment Management first reported a position in Theravance Biopharma in Q3 2016 and held it in 4 quarters.
Zacks Investment Management's Theravance Biopharma position peaked at $861K in Q2 2017.
84 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2017.

Based on Zacks Investment Management's 13F filing for Q3 2017, filed 14 Nov 2017.